Simple Summary When employing a high tumor mutational burden (TMB) as a predictive
biomarker for immune checkpoint inhibitor (ICI) response, one faces various challenges. It is …

Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …

Objective High tumor mutational burden (TMB) is a promising biomarker for patients with
immunotherapy in certain types of solid tumors. This article focuses on exploring possible …

Increasingly, oncologists are turning to tumor mutation burden (TMB) as a biomarker of
response to immune checkpoint inhibitors. However, recent research suggests that TMB …

Background High tumor mutational burden (TMB) is one of the widely researched predictive
biomarkers of immune checkpoint inhibitors and has been shown to be closely related with …

PURPOSE Immune checkpoint inhibitors (ICIs) are used for an increasing number of
indications across various tumor types, as well as several tumor-agnostic indications in …

Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …

Abstract Characterization of tumors utilizing next‐generation sequencing methods, including
assessment of the number of somatic mutations (tumor mutational burden [TMB]), is currently …

Simple Summary Recently, patients with high-TMB tumors received agnostic FDA approval
to be treated with pembrolizumab. However, some high-TMB patients do not show clinical …

Purpose Immunotherapy is regarded as the most promising treatment for cancer. However,
immune checkpoint inhibitors (ICIs) are not effective for all patients. Herein, we conducted a …